| Literature DB >> 35682084 |
Ion Papava1,2,3, Liana Dehelean1,2,3, Radu Stefan Romosan1,2,3, Mariana Bondrescu1,3,4, Cristian Zoltan Dimeny3, Eugenia Maria Domuta5, Felix Bratosin6, Iulia Bogdan6, Mirela Loredana Grigoras6,7, Codruta Victoria Tigmeanu8, Angelica Gherman9, Iosif Marincu5.
Abstract
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection induces a significant inflammatory response that are amplified by persistent stress. The pathophysiology of mental illnesses is explored in terms of inflammatory processes. Thus, anxious, depressed, or psychotic episodes may occur as a result of metabolic and immunological imbalances, as a direct result of their effect on the central nervous system, or as a side effect of the COVID-19 medication protocols. As such, the primary objective of this research is to establish if the psychological profiles of COVID-19 patients change substantially according to illness severity. The secondary objective is to determine if particular biological inflammatory indicators are associated with anxiety, sadness, psychoticism, and paranoid ideation. A cross-sectional study was performed on 90 hospitalized patients admitted during a 3-month period in the COVID-19 unit. All patients received the COPE-60 and SCL-90R questionnaires. Clinical and paraclinical data were collected and the information was classified according to the severity of COVID-19.The hyper-acute inflammation encountered in patients with severe COVID-19 infection characterized 80.0% of patients using disengagement coping methods, significantly more than patients with mild or moderate SARS-CoV-2 infection severity (p-value = 0.012), respectively, 73.3% severe COVID-19 patients engaging in emotion-focused coping strategies based on the COPE-60 scale (p-value = 0.037). Additionally, it was determined that negative coping mechanisms (disengagement) and emotion-focused methods are independent risk factors for developing psychoticism symptoms following acute SARS-CoV-2 infection, based on the SCL-90 questionnaire (OR = 2.07; CI = 1.44-3.01), respectively (OR = 2.92; CI = 1.44-3.01). Elevated white blood cells and monocytes and inflammatory markers, such as fibrinogen, procalcitonin, IL-6, and D-dimers, were also identified as risk factors for psychoticism symptoms in multivariate analysis. It is particularly important to consider the constant mental-state evaluation in patients with severe COVID-19 that might benefit from early intervention before psychotic symptoms onset.Entities:
Keywords: COPE-60; COVID-19; SARS-CoV-2; SCL-90R; severe infection
Mesh:
Year: 2022 PMID: 35682084 PMCID: PMC9180708 DOI: 10.3390/ijerph19116501
Source DB: PubMed Journal: Int J Environ Res Public Health ISSN: 1660-4601 Impact factor: 4.614
COVID-19-severity categories.
| COVID-19 | Characteristics |
|---|---|
| Mild |
Absence of imagistic symptoms Absence of pulmonary lesions Pneumonia affecting less than 20% of the lung area SpO2 of more than 94 percent Absence or mild inflammatory response |
| Moderate |
Impacted lung area between 20% and 50% SpO2 between 94% and 87% The need for oxygen treatment for a brief duration Enhanced inflammatory syndrome |
| Severe |
Hyper-acute inflammatory response Affected lung area >50% Required prolonged oxygen treatment |
Background data of study participants by the severity of COVID-19.
| Variables * | Mild ( | Moderate ( | Severe ( | |
|---|---|---|---|---|
|
| 0.126 | |||
| 18–40 | 13 (43.3%) | 7 (23.3%) | 4 (13.3%) | |
| 40–65 | 9 (30.0%) | 12 (40.0%) | 14 (46.7%) | |
| >65 | 8 (26.7%) | 11 (36.7%) | 12 (40.0%) | |
|
| 0.725 | |||
| Male | 16 (53.3%) | 18 (60.0%) | 19 (63.3%) | |
| Female | 14 (46.7%) | 12 (40.0%) | 11 (36.7%) | |
|
| 0.529 | |||
| Rural | 7 (23.3%) | 11 (36.7%) | 9 (30.0%) | |
| Urban | 23 (76.7%) | 19 (63.3%) | 21 (70.0%) | |
|
|
| |||
| Employed | 22 (73.3%) | 12 (40.0%) | 9 (30.0%) | |
| Unemployed | 4 (13.3%) | 7 (23.3%) | 7 (23.3%) | |
| Retired | 3 (10.0%) | 9 (30.0%) | 11 (36.7%) | |
| Disability retirement | 1 (3.3%) | 2 (6.67%) | 3 (10.0%) | |
|
| ||||
| Cardiovascular | 6 (20.0%) | 11 (36.7%) | 19 (63.3%) |
|
| Metabolic | 5 (16.7%) | 8 (26.7%) | 15 (50.0%) |
|
|
| 10 ± 3.1 | 14 ± 3.8 | 18 ± 6.0 |
|
|
| 9 ± 3.0 | 12 ± 4.2 | 14 ± 4.8 |
|
* Data reported as n(%) unless specified differently; ** Chi-squared test and Fisher’s exact; *** Cardiovascular comorbidities: high blood pressure, chronic heart failure, ischemic heart disease, and stroke; metabolic comorbidities: diabetes mellitus, metabolic syndrome, and thyroid dysfunction.
Laboratory profile of study participants by the severity of COVID-19.
| Variables * | Normal Range | Mild ( | Moderate ( | Severe ( | |
|---|---|---|---|---|---|
| Monocyte (thousands/mm3) | 0.1–1.0 | 13 (43.3%) | 15 (50.0%) | 22 (73.3%) |
|
| WBC (thousands/mm3) | 4.5–11.0 | 16 (53.3%) | 21 (70.0%) | 26 (86.7%) |
|
| Fibrinogen (g/L) | 2–4 g/L | 12 (40.0%) | 17 (56.7%) | 23 (76.7%) |
|
| ESR (mm/h) | 0–22 mm/hr | 14 (46.7%) | 16 (53.3%) | 21 (70.0%) | 0.171 |
| CRP (mg/L) | 0–10 mg/L | 9 (30.0%) | 15 (50.0%) | 19 (63.3%) |
|
| Procalcitonin (μg/L) | 0–0.5 μg/L | 4 (13.3%) | 7 (23.3%) | 14 (46.7%) |
|
| Platelets (thousands/mm3) | 150–450 | 3 (10.0%) | 8 (26.7%) | 12 (40.0%) |
|
| D-dimers (ng/mL) | <250 | 1 (3.3%) | 3 (10.0%) | 10 (33.3%) |
|
| Ferritin (ng/mL) | 20–250 | 3 (10.0%) | 4 (13.3%) | 6 (20.0%) | 0.532 |
| IL-6 (pg/mL) | 0–16 pg/mL | 5 (16.7%) | 8 (26.7%) | 14 (46.7%) |
|
* Data reported as n (% outside normality) unless specified differently; ** Chi-squared test and Fisher’s exact; WBC—White Blood Cells; ESR—Erythrocyte Sedimentation Rate; IL-6—Interleukin 6.
Psychometric scale results of study participants by the severity of COVID-19.
| Variables | Mild ( | Moderate ( | Severe ( | ||
|---|---|---|---|---|---|
|
| |||||
| Disengagement (2) |
| ||||
| >Median | 13 (43.3%) | 18 (60.0%) | 24 (80.0%) | ||
| ≤Median | 17 (56.7%) | 12 (40.0%) | 6 (20.0%) | ||
| Engagement (3) | 0.573 | ||||
| >Median | 18 (60.0%) | 20 (66.7%) | 16 (53.3%) | ||
| ≤Median | 12 (40.0%) | 10 (33.3%) | 14 (46.7%) | ||
| Emotion Focused (2) |
| ||||
| >Median | 14 (46.7%) | 13 (43.3%) | 22 (73.3%) | ||
| ≤Median | 16 (53.3%) | 17 (56.7%) | 8 (26.7%) | ||
| Problem Focused (3) | 0.429 | ||||
| >Median | 17 (56.7%) | 14 (46.7%) | 12 (40.0%) | ||
| ≤Median | 13 (43.3%) | 16 (53.3%) | 18 (60.0%) | ||
|
| 1.77 [1.09–2.96] | 2.25 [1.21–3.18] | 2.94 [1.72–3.96] |
| |
| Depression | 4 (13.3%) | 7 (23.3%) | 11 (36.7%) | 0.107 | |
| Anxiety | 15 (50.0%) | 19 (63.3%) | 20 (66.7%) | 0.378 | |
| Paranoid ideation | 12 (40.0%) | 13 (43.3%) | 22 (73.3%) |
| |
| Psychoticism | 1 (3.3%) | 2 (6.7%) | 8 (26.7%) |
|
COPE—Coping Orientation to Problems Experienced Inventory; SCL-90—Symptom Checklist-90.
Comparison of laboratory parameters stratified by psychological symptoms on the SCL-90 scale.
| Variables * | Normal Range | Depression | Anxiety | Paranoid Ideation | Psychoticism | |
|---|---|---|---|---|---|---|
| Monocyte | 0.1–1.0 thousands/mm3 | 0.8 [0.3–1.2] | 0.9 [0.2–1.4] | 1.8 [0.6–3.2] | 2.7 [1.1–4.8] |
|
| WBC | 4.5–11.0 thousands/mm3 | 11.6 [7.3–13.9] | 11.4 [7.0–12.2] | 13.6 [8.1–14.7] | 14.9 [8.9–15.6] |
|
| Fibrinogen | 2–4 g/L | 2.2 [0.5–4.1] | 3.0 [0.7–5.2] | 4.4 [1.3–6.0] | 4.9 [1.7–7.5] | 0.138 |
| ESR | 0–22 mm/hr | 24.8 [16.3–31.5] | 25.2 [15.4–33.8] | 22.7 [13.1–29.6] | 29.4 [18.0–39.7] |
|
| CRP | 0–10 mg/L | 22.0 [11.8–34.3] | 26.8 [13.2–37.2] | 23.9 [13.6–33.1] | 29.1 [15.8–40.3] | 0.185 |
| Procalcitonin | 0–0.5 μg/L | 14.3 [8.1–22.6] | 12.7 [7.4–24.9] | 16.4 [8.8–27.2] | 18.3 [8.2–31.4] | 0.063 |
| Platelets | 150–450 | 263 [199–372] | 259 [184–337] | 246 [180–325] | 239 [172–321] | 0.692 |
| D-dimers | <250 ng/mL | 289 [164–493] | 346 [201–528] | 302 [196–418] | 294 [171–397] |
|
| Ferritin | 20–250 ng/mL | 79 [37–155] | 84 [49–182] | 103 [57–207] | 88 [51–194] | 0.107 |
| IL-6 | 0–16 pg/mL | 39.4 [17.0–66.7] | 42.7 [21.8–80.4] | 55.4 [20.9–83.6] | 93.3 [42.4–126.0] |
|
* Kruskal–Wallis test—significance at 0.05; SCL-90—Symptom Checklist-90; WBC—White Blood Cells; ESR—Erythrocyte Sedimentation Rate; IL-6—Interleukin.
Comparison of laboratory parameters stratified by COPE-60 categories.
| Variables * | Normal Range | Disengagement | Engagement | Emotion Focused | Problem Focused | |
|---|---|---|---|---|---|---|
| Monocyte | 0.1–1.0 thousands/mm3 | 2.9 [1.0–4.9] | 0.8 [0.3–1.1] | 1.6 [0.8–2.5] | 1.2 [0.5–1.8] |
|
| WBC | 4.5–11.0 thousands/mm3 | 14.9 [7.7–19.8] | 11.0 [7.2–14.2] | 11.6 [7.2–14.7] | 15.1 [8.9–15.6] |
|
| Fibrinogen | 2–4 g/L | 2.2 [0.5–4.1] | 3.3 [0.8–4.1] | 4.1 [1.3–5.8] | 4.7 [1.8–7.3] | 0.266 |
| ESR | 0–22 mm/hr | 23.6 [16.3–31.5] | 24.1 [15.0–32.4] | 22.3 [12.9–29.6] | 25.9 [16.6–33.5] | 0.184 |
| CRP | 0–10 mg/L | 21.9 [11.8–34.3] | 25.7 [13.9–37.6] | 23.9 [13.6–33.1] | 29.1 [15.8–40.3] | 0.091 |
| Procalcitonin | 0–0.5 μg/L | 18.5 [8.1–22.6] | 12.1 [7.0–23.8] | 15.7 [8.2–26.4] | 17.4 [8.0–30.9] |
|
| Platelets | 150–450 | 280 [199–372] | 244 [176–323] | 219 [176–369] | 222 [162–301] | 0.549 |
| D-dimers | <250 ng/mL | 317 [164–493] | 330 [216–498] | 310 [183–403] | 289 [174–386] | 0.247 |
|
| 20–250 ng/mL | 94 [37–155] | 88 [52–191] | 107 [61–216] | 83 [52–188] | 0.315 |
| IL-6 | 0–16 pg/mL | 41.6 [17.0–66.7] | 43.2 [21.0–81.5] | 53.8 [21.6–82.9] | 94.7 [41.8–122.8] |
|
* Kruskal–Wallis test—significance at 0.05; COPE—Coping Orientation to Problems Experienced Inventory; WBC—White Blood Cells; ESR—Erythrocyte Sedimentation Rate; IL-6—Interleukin 6.
Risk factor analysis for developing psychoticism during SARS-CoV-2 infection.
| Univariate OR (95% CI) | Multivariate OR (95% CI) | |||
|---|---|---|---|---|
|
| ||||
| Disengagement | 2.64 (1.82–3.97) | 0.004 | 2.07 (1.44–3.01) |
|
| Engagement | 2.09 (1.16–3.44) | 0.181 | 1.85 (1.06–2.74) | 0.053 |
| Emotion Focused | 3.35 (2.24–5.83) | 0.001 | 2.92 (1.26–4.05) |
|
| Problem Focused | 1.88 (1.13–6.08) | 0.127 | 1.34 (1.09–2.71) | 0.094 |
|
| ||||
| Monocyte | 4.92 (2.58–6.67) | <0.001 | 4.38 (3.01–5.64) |
|
| WBC | 5.19 (2.26–6.08) | <0.001 | 3.42 (2.07–4.62) |
|
| Fibrinogen | 3.07 (2.19–4.86) | 0.002 | 1.89 (1.16–3.07) |
|
| ESR | 1.64 (1.73–2.44) | 0.009 | 1.09 (0.92–1.36) | 0.268 |
| CRP | 1.79 (1.21–2.50) | 0.002 | 1.26 (0.88–1.54) | 0.107 |
| Procalcitonin | 3.03 (2.07–4.96) | <0.001 | 2.32 (1.29–3.88) |
|
| Platelets | 1.18 (0.97–1.32) | 0.216 | 1.02 (0.69–1.31) | 0.424 |
| D-dimers | 3.82 (2.33–5.65) | <0.001 | 3.14 (2.06–4.38) |
|
| Ferritin | 1.70 (1.28–2.57) | <0.001 | 1.38 (1.01–1.84) |
|
| IL-6 | 5.23 (2.23–6.11) | <0.001 | 3.49 (2.28–4.70) |
|
| SCL-90 | 2.14 (1.47–2.89) | <0.001 | 1.33 (1.15–2.01) |
|
COPE—Coping Orientation to Problems Experienced Inventory; SCL-90—Symptom Checklist-90.